Matinas BioPharma Holdings Inc
F:6LJ
Income Statement
Earnings Waterfall
Matinas BioPharma Holdings Inc
Income Statement
Matinas BioPharma Holdings Inc
| Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+65%
|
0
+21%
|
0
N/A
|
0
-50%
|
0
-65%
|
0
N/A
|
1
N/A
|
2
+100%
|
3
+50%
|
4
+34%
|
3
-25%
|
2
-33%
|
1
-49%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||||
| Operating Expenses |
0
|
0
|
(19)
|
(7)
|
(12)
|
(18)
|
(24)
|
(24)
|
(23)
|
(25)
|
(25)
|
(26)
|
(28)
|
(28)
|
(28)
|
(27)
|
(26)
|
(26)
|
(25)
|
(24)
|
(23)
|
(22)
|
(20)
|
(15)
|
|
| Selling, General & Administrative |
0
|
0
|
(8)
|
(2)
|
(5)
|
(7)
|
(10)
|
(11)
|
(11)
|
(11)
|
(10)
|
(10)
|
(10)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(10)
|
(10)
|
(10)
|
(9)
|
(9)
|
(6)
|
|
| Research & Development |
0
|
0
|
(11)
|
(4)
|
(7)
|
(11)
|
(14)
|
(10)
|
(9)
|
(10)
|
(15)
|
(16)
|
(18)
|
(17)
|
(17)
|
(16)
|
(15)
|
(15)
|
(14)
|
(14)
|
(14)
|
(13)
|
(11)
|
(5)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
(4)
|
(4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
|
| Operating Income |
0
N/A
|
0
N/A
|
(19)
N/A
|
(7)
+61%
|
(12)
-65%
|
(18)
-46%
|
(24)
-37%
|
(24)
0%
|
(23)
+4%
|
(25)
-5%
|
(25)
-1%
|
(26)
-6%
|
(27)
-4%
|
(26)
+5%
|
(25)
+5%
|
(22)
+9%
|
(23)
-1%
|
(23)
-3%
|
(24)
-2%
|
(24)
+1%
|
(23)
+1%
|
(22)
+8%
|
(20)
+6%
|
(15)
+27%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
1
|
0
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
(4)
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
|
| Pre-Tax Income |
0
N/A
|
0
N/A
|
(17)
N/A
|
(5)
+71%
|
(11)
-111%
|
(16)
-51%
|
(22)
-39%
|
(22)
+0%
|
(22)
+4%
|
(23)
-6%
|
(23)
-2%
|
(24)
-4%
|
(25)
-5%
|
(24)
+5%
|
(21)
+13%
|
(21)
+2%
|
(21)
-1%
|
(21)
-3%
|
(23)
-8%
|
(23)
-1%
|
(23)
+1%
|
(21)
+8%
|
(24)
-15%
|
(18)
+26%
|
|
| Net Income | |||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
0
|
0
|
(17)
|
(5)
|
(11)
|
(16)
|
(22)
|
(22)
|
(22)
|
(23)
|
(23)
|
(24)
|
(25)
|
(24)
|
(21)
|
(21)
|
(21)
|
(21)
|
(23)
|
(23)
|
(23)
|
(21)
|
(24)
|
(18)
|
|
| Net Income (Common) |
0
N/A
|
0
N/A
|
(18)
N/A
|
(5)
+71%
|
(11)
-111%
|
(17)
-52%
|
(23)
-39%
|
(23)
+0%
|
(22)
+3%
|
(24)
-5%
|
(24)
-1%
|
(24)
-3%
|
(25)
-4%
|
(24)
+5%
|
(21)
+13%
|
(21)
+2%
|
(21)
-1%
|
(21)
-3%
|
(23)
-8%
|
(23)
-1%
|
(23)
+1%
|
(21)
+8%
|
(24)
-15%
|
(18)
+26%
|
|
| EPS (Diluted) |
0
N/A
|
0
N/A
|
-0.13
N/A
|
-0.03
+77%
|
-0.06
-100%
|
-0.09
-50%
|
-0.12
-33%
|
-0.12
N/A
|
-0.11
+8%
|
-0.11
N/A
|
-5.63
-5 018%
|
-0.11
+98%
|
-0.12
-9%
|
-0.11
+8%
|
-4.84
-4 300%
|
-0.09
+98%
|
-0.1
-11%
|
-0.1
N/A
|
-5.28
-5 180%
|
-5.34
-1%
|
-4.59
+14%
|
-4.19
+9%
|
-4.98
-19%
|
-3.54
+29%
|
|